When your doctor suggests switching from Humira to a biosimilar, it’s natural to feel uneasy. You’ve been on the same medication for years. It works. You know how your body reacts to it. Now you’re being asked to try something new-something you’ve never heard of before. You’re not alone. Biosimilars are one of the biggest opportunities to cut healthcare costs without sacrificing care, yet most patients don’t trust them. And it’s not because they’re stubborn. It’s because they’ve been left in the dark.
What Exactly Is a Biosimilar?
A biosimilar is not a generic. That’s the first thing you need to understand. Generics are copies of simple chemical drugs-like ibuprofen or metformin. They’re made in labs using precise formulas. If you take a generic version of ibuprofen, it’s chemically identical to the brand name. No surprises. Biosimilars are different. They’re copies of biologic drugs-complex medicines made from living cells. Think of them like a handmade quilt. Even if two quilters use the same pattern and fabric, each quilt has tiny differences in stitching. That’s how biosimilars work. They’re not exact copies, but they’re so close that no meaningful difference shows up in how they work in your body. The FDA requires biosimilars to go through more than 10 years of testing: thousands of lab tests, animal studies, and clinical trials involving hundreds of patients. The goal? Prove there’s no difference in safety, effectiveness, or side effects compared to the original drug. That’s not something you can fake. The first FDA-approved biosimilar, Zarxio, came out in 2015. Since then, 74 have been approved as of April 2025.Why Are Patients So Hesitant?
Most patients don’t know what biosimilars are. A 2025 survey by the Evernorth Research Institute found only 31% of people with chronic conditions had even heard of them. Meanwhile, 64% of doctors had. That gap matters. When a doctor says, “We’re switching you to a biosimilar,” without explaining what it is, patients hear: “We’re giving you a cheaper version.” And in medicine, cheaper often feels like worse. Some patients have had bad experiences. One Reddit user, ChronicPainPatient87, shared how their doctor switched them to a biosimilar for Humira without warning. They had a flare-up. They didn’t know if it was the drug, stress, or bad luck-but they blamed the biosimilar. That fear sticks. A 2025 study in the Journal of Managed Care & Specialty Pharmacy found 79% of patients worried biosimilars wouldn’t work as well. Sixty-three percent feared new or worse side effects. And here’s the cruel twist: even though biosimilars save the system billions, patients rarely see those savings. For pegfilgrastim, biosimilars cut out-of-pocket costs by nearly half in the first cycle. But for many other drugs-like infliximab-patient costs stayed the same after biosimilars entered the market. Insurance companies and pharmacy benefit managers (PBMs) often don’t pass savings along. So patients pay the same, but they’re still scared.
Biosimilars vs Generics: The Real Difference
It’s easy to think, “If generics are safe, why not biosimilars?” But the science doesn’t work the same way. Generics: Made from chemicals. Simple molecules. Cost $2-3 million to develop. Take 3-4 years. Nearly identical to the original. Biosimilars: Made from living cells. Complex proteins. Cost $100-250 million to develop. Take 8-10 years. Very similar-but not identical-at the molecular level. But here’s the key: those tiny differences don’t affect how the drug works in your body. Over 100,000 patients have been studied. No meaningful safety or effectiveness gaps. Think of it like two identical twins. They look almost the same. Same height, same voice, same DNA. But one has a scar on their left hand. Does that make them less reliable? No. The scar doesn’t change who they are. Biosimilars are like that twin. Minor differences exist, but they don’t change the outcome.Why Aren’t More People Using Them?
You’d think with 74 approved biosimilars and $56 billion in savings over the past decade, adoption would be soaring. But it’s not. For most biologics, biosimilar use is under 10%. That’s shocking. Why? Three big reasons:- Doctors don’t feel confident. Many physicians were never trained on biosimilars. They don’t know how to explain them. They fear complaints or flare-ups.
- Insurance rules are messy. PBMs often push patients toward biosimilars-but don’t lower co-pays. That makes patients feel tricked.
- Manufacturers fight back. Big pharma uses “pay-for-delay” deals to block biosimilars from entering the market for up to 18 months longer than they should.
Health and Wellness